Pipeline › olatorepatide
olatorepatide
Not FDA-approved, and in phase 2 development, not authorised in the European Union. 2 active trials, the next due to complete 2026-11-13.
incretin (auto-detected) agonist, unknown, from Regeneron Pharmaceuticals. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase2
- Target
- incretin (auto-detected)
- Route
- unknown
- Sponsor
- Regeneron Pharmaceuticals
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 2 (0 in phase 3)
- Participants enrolled
- 480
- Trials with a reporting date
- 2
- Approved FDA submissions
- 0
Recent changes
| Detected | Change | Trial | Detail | Phase |
|---|---|---|---|---|
| 2026-08-21 | New trial registered | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes NCT07685808 · Regeneron Pharmaceuticals | Recruiting, n=360 | P2 |
| 2026-08-21 | New trial registered | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US NCT07431086 · Regeneron Pharmaceuticals | Active, not recruiting, n=120 | P2 |
When these trials report
Next 2 of 2 active trials by estimated primary completion.
| Est. completion | Trial | Sponsor | Phase | Participants |
|---|---|---|---|---|
| 2026-11-13 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US NCT07431086 · Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Regeneron Pharmaceuticals | P2 | 120 |
| 2028-01-21 | Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes NCT07685808 · Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Regeneron Pharmaceuticals | P2 | 360 |
Indications under study
Overweight or Obesity.